Capivasertib, a selective oral AKT inhibitor, has demonstrated substantial efficacy in hormone receptor–positive, HER2–negative advanced breast cancer, particularly among patients with AKT pathway mutations. This evidence concerns the gene NR4A1 and breast carcinoma.